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Abstract
This work describes a new specific, sensitive, and rapid stable isotope dilution method for the 
simultaneous detection of the organophosphorus nerve agents (OPNAs) tabun (GA), sarin (GB), 
soman (GD), cyclosarin (GF), VR, VX, and VM adducts to tyrosine (Tyr). Serum, plasma, and 
lysed whole blood samples (50 µL) were prepared by protein precipitation followed by digestion 
with Pronase. Specific Tyr adducts were isolated from the digest by a single solid phase extraction 
(SPE) step, and the analytes were separated by reversed-phase ultra high performance liquid 
chromatography (UHPLC) gradient elution in less than 2 min. Detection was performed on a triple 
quadrupole tandem mass spectrometer using time-triggered selected reaction monitoring (SRM) in 
positive electrospray ionization (ESI) mode. The calibration range was characterized from 0.100–
50.0 ng/mL for GB– and VR– Tyr and 0.250–50.0 ng/mL for GA–, GD–, GF–, and VX/VM–Tyr 
(R2 ≥ 0.995). Inter- and intra-assay precision had coefficients of variation of ≤17 and ≤10%, 
respectively, and the measured concentration accuracies of spiked samples were within 15% of the 
targeted value for multiple spiking levels. The limit of detection was calculated to be 0.097, 0.027, 
0.018, 0.074, 0.023, and 0.083 ng/mL for GA–, GB–, GD–, GF–, VR–, and VX/VM–Tyr, 
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respectively. A convenience set of 96 serum samples with no known nerve agent exposure was 
screened and revealed no baseline values or potential interferences. This method provides a simple 
and highly specific diagnostic tool that may extend the time postevent that a confirmation of nerve 
agent exposure can be made with confidence.
The first confirmed large-scale use of organophosphorus nerve agents (OPNAs) in the 1984 
Iraq–Iran conflict1 emphasized the need for sensitive diagnostic biomarkers and methods for 
detection of OPNA exposure.2 Since then, there have been several additional large-scale 
uses of OPNAs including the sarin (GB) gas attacks in Matsumoto in 1994,3 Tokyo in 
1995,4 and Syria in 2013.5 While measurement of environmental samples plays a key role in 
investigations of alleged production or use of chemical weapons, detection of nerve agent 
biomarkers in clinical samples can provide critical evidence of human exposure. Such 
analyses may be crucial to separating the “worried-well” from exposed individuals in the 
case of a large exposure event.
Nerve agents are rapidly metabolized in vivo and exist partially as free agent (for a short 
time after exposure), partially as degradation products or metabolites, and partially as 
covalent adducts to macromolecules.6–8 Measurement of cholinesterase (ChE) activity in 
blood by the Ellman assay is widely used as a preliminary test to diagnose exposure to 
OPNAs.9 Unfortunately, this assay cannot differentiate between exposure to Schedule 1 
nerve agents prohibited by the Chemical Weapons Convention (CWC) and exposure to 
commonly used organophosphorus (OP) pesticides. Additionally, reliance upon the Ellman 
assay requires routine measurement of baseline activity values to account for intra- and 
inter-individual activity variations.10 More specific methods based on the detection of nerve 
agent hydrolysis products such as O-alkyl methylphosphonic acid have also been developed 
for urine11,12 and blood samples;13 however, samples must be collected shortly after 
exposure because these metabolites are rapidly eliminated from the body.12
Fluoride reactivation has proven to be a highly sensitive method for detecting OPNA 
exposure and works by displacing the adducted OP moiety from acetylcholinesterase 
(AChE), butyrylcholinesterase (BChE), human serum albumin (HSA), and fibrous tissue 
with fluoride ions in turn regenerating the fluorinated agent.14–16 Unfortunately, loss of the 
agent defining O-alkyl group from cholinesterases through an enzyme mediated hydrolysis 
process known as “aging” eliminates the possibility of refluoridation and makes the 
detection of rapidly aging OPNA adducts such as soman (GD) unlikely.14 Likewise, 
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displacement of the OP adduct from BChE and AChE after oxime therapy reduces the 
effectiveness of this otherwise sensitive diagnostic approach.17
Detecting OPNAs adducted to macromolecules in blood is an alternative approach with 
many advantages. Most notably, the extended lifetime relative to that of hydrolysis products 
or free agent makes protein adducts ideal for retrospective detection of nerve agent 
exposure.18 Methods have been developed to detect OPNAs adducted to the catalytic serine 
(Ser) residue of BChE (Ser-198)18–21 and tyrosine (Tyr-411) of HSA.17,22–24 While BChE 
has proven to be an excellent biomarker protein for assessing OPNA exposure,6,25,26 the 
aging process that can occur removes the structural identity of the adducted nerve agent. 
Conversely, OPNA adducts to HSA do not “age” and persist following oxime therapy.27–29
Proteins other than HSA have also been reported to contain OPNA–Tyr adducts; however, 
the high concentration of HSA, even after depletion, makes these additional protein 
biomarkers difficult to detect at low OPNA exposure levels.27 A method has been 
established for the determination of GD and tabun (GA) adducts in guinea pigs 7 days 
following exposure and subsequent oxime treatment.17,22,24 GB, VX, VR, and cyclosarin 
(GF) have also been reported to covalently bind to Tyr-411 of HSA.17,22,28 Even under 
conditions that would typically cause clinical samples to age and nerve agent specificity to 
be lost, analysis of Tyr adducts allows identification of the specific nerve agents of 
exposure.29
This work reports a newly developed sensitive and accurate method for the simultaneous 
detection of GA, GB, GD, GF, VR, and VX/VM adducted to Tyr in total protein. Pronase 
digestion followed by solid phase extraction (SPE) and ultrahigh pressure liquid 
chromatography-isotope dilution tandem mass spectrometry (UHPLC-MS/MS) was used to 
isolate OPNA–Tyr adducts from human serum and plasma that was exposed to OPNAs in 
vitro. Proteins were precipitated from plasma, serum, or whole lysed blood by the addition 
of acetone, and the resulting dried pellet was digested with Pronase. The OPNA-modified 
Tyr was purified by a single solid phase extraction (SPE) step, separated by UHPLC, and 
detected on a triple quadrupole tandem mass spectrometer by time function selected reaction 
monitoring (SRM) in positive electrospray ionization (ESI) mode in under 2 min. 




The following materials were purchased from Fisher Scientific (Hanover Park, IL): 
ammonium bicarbonate, HPLC-grade methanol, Optima-grade acetone, and LC-MS-grade 
formic acid. Protease Type XIV from Streptomyces griseus (Pronase) was purchased from 
Sigma-Aldrich (P5147, St. Louis, MO). HPLC-grade acetonitrile was purchased from Tedia 
(Fairfield, OH). Strata SDB-L 96-well (50 mg) SPE plates were purchased from 
Phenomenex (Torrance, CA). Cibacron Blue beads were purchased from Pierce 
Biotechnology (Rockford, IL). Synthetically prepared native and isotopically labeled Tyr 
adducts (≥95% purity) were obtained from Battelle Memorial Institute (Columbus, OH) and 
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the Defence Science and Technology Laboratory (Porton Down, U.K.). Isotopically labeled 
GA–Tyr was enriched with D5-ethyl, and GB-, GD-, GF-, VR-, and VX–Tyr were enriched 
with 13CD3 at the phosphomethyl position. A convenience set of 96 serum samples was 
purchased from Tennessee Blood Services (Memphis, TN) to assess background levels of 
each biomarker. Additionally, pooled plasma for preparing inhibited quality control (QC) 
materials and whole blood samples for determining method compatibility were purchased 
from Tennessee Blood Services. Pooled serum was purchased from Bioreclamation Inc. 
(Westbury, NY). Plasma and serum pools were screened by the vendors, in accordance with 
FDA regulations, to be free of Hepatitis B, Hepatitis C, Syphilis, and HIV. This study used 
de-identified blood acquired from commercial sources, and thus, the work did not meet the 
definition of human subjects as specified in 45 CFR 46.102 (f).
Preparation of Calibrators and Quality Controls
Synthetic GA–, GB–, GD–, GF–, VR–, and VX/VM–Tyr standards (Figure 1) were 
analyzed for amino acid content by Midwest Biotech (Fishers, IN), and purity estimates 
were adjusted accordingly. Individual stock solutions for each native and isotopically 
labeled standard (1.00 mg/mL) were prepared in HPLC-grade water and stored at −20 °C. 
The native stock solutions were combined and diluted to prepare eight calibrators at a final 
concentration for each of 0.100, 0.250, 0.500, 1.00, 5.00, 10.0, 25.0, and 50.0 ng/mL in 
HPLC-grade water. The isotopically labeled standard stock solutions were combined to 
prepare a single internal standard (ISTD) solution at a final concentration for each of 10 
ng/mL in HPLC-grade water.
Three QC samples were prepared: QC low (QCL), QC high (QCH), and QC digest (QCD). 
The QCL and QCH samples were prepared by spiking 1.00 mg/mL native OPNA–Tyr stock 
solutions into HPLC-grade water. The QCD samples were prepared by pooling previously 
characterized GA- and GB-spiked serum with GD- and GF-spiked plasma to monitor for the 
completeness of digestion. Plasma spiked with V-series agents was intentionally not 
included in the QCD pool due to the already low concentrations of VR– and VX–Tyr in 
undiluted plasma. The concentrations of OPNA–Tyr adducts were characterized for each 
QC sample as part of the method validation in a set of 20 different experiments.
Preparation of Agent-Spiked Materials for use as Quality Control Samples
A single pool of plasma was divided into seven parts and spiked with nerve agent so that 
each part was exposed to a single nerve agent or blank (isopropyl alcohol) at the Edgewood 
Chemical and Biological Center (Edgewood, MD). Specifically, 20.0 µL of a 1.00 mg/mL 
solution of GA, GB, GD, GF, VR, or VX nerve agent in isopropyl alcohol was added to 1.00 
L of plasma at room temperature (RT) and gently shaken for 20 min for a final concentration 
of 20.0 ng/mL nerve agent in plasma. At the Battelle Memorial Institute, a pool of plasma 
(1.00 L) was spiked with 100 µL of a VM nerve agent stock (825 µg/mL in plasma) and 
stirred for 1 h at RT for a final concentration of 75.0 ng/mL VM in plasma. In a similar 
fashion, Battelle divided and spiked a pool of serum with a serum stock solution of GA (877 
µg/mL) or GB (1050 µg/mL) to afford final concentrations of 1580 and 396 ng/mL in serum, 
respectively. All plasma and serum materials were assayed for BChE activity using a 
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modified Ellman assay9 before and after spiking, and screened for free/excess agent prior to 
storage at −80 °C.
Sample Preparation
Plasma, serum, or whole lysed blood (50 µL) was transferred to a 2 mL conical bottom 96-
well plate, and acetone (300 µL) was added for protein precipitation. The samples were 
sealed and centrifuged at 3000g for 5 min at 20 °C to pelletize proteins. Supernatant was 
removed by aspiration, and the remaining pellet was allowed to air-dry for 5 min at room 
temperature. The dried pellet was reconstituted in 400 µL of ammonium bicarbonate (50 
mM, pH 7.8) with mixing. ISTD solution (20 µL) was added to all processed wells. 
Calibrators (50 µL) were spiked into wells containing reconstituted pellets formed from 
blank plasma for the purpose of matrix matching. To ensure homogeneity between 
calibrators, QCs, and unknowns, HPLC-grade water (50 µL) was added to all unknowns, 
reference materials, and digest controls. Pronase solution (100 µL of 10 mg/mL in 50 mM 
ammonium bicarbonate, pH 7.8) was added to each well. The plate was sealed with adhesive 
foil and incubated at 50 °C for 1.5 h with intermittent mixing. The entire volume (~570 µL) 
of the sample digest was added to a Strata SDB-L 96-well SPE plate that was first 
conditioned with methanol (1 mL) and then water (1 mL). The plate was washed with 10% 
methanol in water (2 × 1 mL). The Tyr adducts were eluted with methanol (500 µL) into a 
clean 2 mL 96-well receiving plate. All samples were evaporated to dryness under nitrogen 
at 50 °C using a Porvair Ultravap (Porvair Sciences, Leatherhead, U.K.). The dried samples 
were reconstituted in HPLC-grade water (75 µL), transferred to an Eppendorf 96-well PCR 
plate, and heat sealed with pierceable foil.
UHPLC-MS/MS
The chromatographic system consisted of an Agilent 1290 binary pump, refrigerated 
autosampler, and temperature controlled column compartment (Santa Clara, CA). Separation 
was performed on an Acquity HSS-T3, 1.8 µm, 50 × 1.0 mm analytical column (Waters, 
Milford, MA) at 60 °C. Water with 0.1% formic acid (mobile phase A, MPA) and 
acetonitrile with 0.1% formic acid (mobile phase B, MPB) made up the binary mobile phase, 
which was delivered at a flow rate of 250 µL/min. Following a 6 s needle wash in MPB, 
samples were injected (5 µL) on column with initial conditions set to 98% MPA and 2% 
MPB. A linear gradient was used to reach 40% MPB at 2 min followed by an immediate 
return to initial conditions for column regeneration and a total run time of 2.5 min. The 
extra-column volume of this system was found to be 10 µL, while the gradient delay volume 
was determined to be 105 µL in loop mainpass mode and 65 µL in loop bypass mode. To 
reduce the gradient delay volume and potential for loop carryover, the autosampler state was 
set to bypass mode at 12 s (10 × injection volume, 50 µL) following sample injection.
The UHPLC eluent was directed to an Agilent 6460 triple quadrupole mass analyzer with an 
ESI source operating in positive ionization mode. Data were acquired with Mass Hunter 6.0 
in dynamic SRM mode monitoring the two most selective and sensitive transitions for the 
native Tyr adducts (quantitation and confirmation transitions) and a single transition for the 
labeled Tyr adducts. Ionization source parameters were optimized by post column infusion 
of a 100 ng/mL solution of VR–Tyr in HPLC-grade water at a flow rate of 5 µL/min. During 
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the infusion experiment, the LC pump was set to deliver 23% MPB at 245 µL/min 
corresponding to the approximate solvent composition in source at the elution time of VR–
Tyr, factoring in gradient delay, column void, and post column volume. The optimized 
source settings were found to be 200 °C sheath gas at 11 L/min, 300 °C drying gas at 8 L/
min, nebulizer gas at 60 psi, nozzle voltage of 1000 V, and capillary voltage of 3500 V. 
Optimized parameters for the fragmentor voltage, collision energy (CE), and cell accelerator 
(CA) voltage were independently collected for each native and labeled Tyr adduct (Table 1). 
It is important to note that the nerve agents VX and VM differ in structure only by the 
leaving group and are indistinguishable from one another once adducted to proteins through 
phosphorylation. For this reason, the same mass spectrometer settings were used to identify 
transitions for VX–Tyr and VM–Tyr.
Calibration curves were constructed by plotting the response ratio (analyte area divided by 
internal standard area) versus the expected calibrator concentration. Linear regression was 
used to fit the data with 1/x weighting as determined by residual analysis. The origin was not 
forced through zero. The peak area ratio of the quantitation (quant) to confirmation (conf) 
transitions were used to calculate the confirmation ion ratio (CIR), a value established for 
each adduct and used to confirm detection.
Method Validation
Data from 20 replicate calibration curves and QC samples were evaluated to assess 
accuracy, precision, linearity, lowest reportable limit (LRL), and limits of detection (LOD) 
for each analyte. A maximum of two runs were prepared and analyzed per day over the span 
of two months by three separate analysts. Accuracy and inter-assay precision were 
calculated using the 0.250, 2.50, and 25.0 ng/mL calibrators. Intra-assay precision was 
calculated on five individual preparations of each QC level within a single batch. The LOD 
was calculated from the standard deviation of the concentration of the lowest four calibrators 
per analyte, as described by Taylor.30 Method ruggedness was investigated for five digestion 
parameters, which were not normalized by isotope dilution and therefore expected to have 
the greatest impact on method variance. Temperature, time, Pronase concentration, digestion 
buffer concentration, and pH were separately evaluated against the validated conditions 
using the QCD or QCL samples at values ±20% of the final conditions.
Matrix Effects and Extraction Recovery
Matrix effects and extraction recovery were evaluated by a pre/post-SPE spiking experiment 
performed in triplicate. Blank serum was processed through the precipitation and digestion 
steps and split into two samples prior to SPE. The resulting two identical blank digests were 
identified as the pre- and postspiked samples. Prior to SPE, the prespike sample was spiked 
with 50 µL of the 1.00 ng/mL standard, and the postspike sample was spiked with 50 µL of 
water. Both samples were extracted by SPE, and the eluent was removed by evaporation. 
The prespike extract was reconstituted in 50 µL of water and 50 µL of the ISTD solution. 
The postspike extract was reconstituted in 50 µL of the 1.00 ng/mL standard and 50 µL of 
the ISTD solution. These samples were analyzed and compared to a matrix-free solution 
containing 50 µL of the 1.00 ng/mL standard and 50 µL of the ISTD solution. The average 
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of the response ratio of the prespike was compared to that of the postspike to assess 
extraction recovery:
The average of the response ratio of the postspike was compared to that of the matrix-free 
solution to assess the matrix effect in terms of ionization efficiency:
This process was used to evaluate various conditioning, loading, washing, and elution steps 
on several SPE phases during method development.
Safety Considerations
Nerve agent adducts to Tyr are not expected to pose a risk greater than that of free Tyr. 
Universal safety precautions for handling biological samples should be strictly adhered to at 




There are several approaches to enrich HSA from serum or plasma;31 however, these 
techniques are semiselective processes that require proper internal standards to account for 
losses in recovery of the protein.32 Due to the lack of an isotopically labeled nerve agent 
adduct to HSA, total protein was digested without enrichment. The internal standard 
solution was added to each sample at the earliest possible step (following the removal of the 
protein precipitation solvent) and was present during all remaining steps, including 
digestion. The calibrator solutions were added to blank matrix at the same step, ensuring 
normalized quantitation by matrix matching and isotope dilution.
This reported method digests total protein and not explicitly HSA nerve agent adducts. The 
difference between samples containing total protein and samples enriched for HSA was 
evaluated by processing G-series nerve-agent-spiked plasma using the two approaches 
(Table 2). In brief, nerve-agent-spiked samples were either enriched with HSA using 
Cibacron Blue prior to Pronase digestion, as described by Andacht et al.,32 or treated using 
the precipitation method, described here, without enrichment. When compared, plasma 
spiked with GB, GD, and GF had similar Tyr adduct values for HSA-enriched and total 
protein samples, suggesting HSA as the primary source of the OPNA–Tyr adducts 
measured. Interestingly, plasma spiked with GA showed greater differences between the two 
sample preparations. The value calculated for GA–Tyr was within the characterized method 
limits for both preparations, but the value for HSA-enriched sample was significantly lower 
and more variable than that for samples prepared by total protein precipitation. This finding 
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is consistent with observations of the GA–Tyr adduct being acid labile, perhaps similar to 
reported acid hydrolysis of GA adducts to cholinesterases,33–35 as the HSA enrichment 
protocol incorporates trichloroacetic acid to precipitate the protein following enrichment 
with Cibacron Blue.
Significant attention was given to the optimization of conditions and the ruggedness 
evaluation of the digestion because protein adducted with isotopically labeled nerve agent 
was not available and a nonspecific protease was used. To optimize digestion conditions, 
temperature, pH, digestion time, Pronase concentration, and buffer concentrations were 
varied ±20% using the QCD materials to identify the most reproducible conditions. 
Temperature, pH, Pronase concentration, and buffer concentration had insignificant 
influence on measured OPNA–Tyr adducts when varied ±20%; however, digestion time had 
significant impact on the calculated values, particularly for GA–Tyr. The GA–Tyr values 
decreased as the digestion time increased beyond 1 h, despite the use of basic pH conditions, 
which have previously been shown to reduce degradation of GA adducts.34 After 2 h of 
digestion, the GA–Tyr concentration was nearly 3-fold lower than those collected after 1 h 
at 50 °C. The values for GB–, GD–, and GF–Tyr increased beyond 1 h of digestion and 
plateaued at 1.5 h at 50 °C. A digestion time of 1.5 h was chosen for the robustness of the 
majority of Tyr adducts in the method. Despite the sacrifice in robustness for the digestion 
of GA–Tyr, the characterized QCD values were within acceptable limits of precision (CV ≤ 
20%).
The effect of sample integrity and composition on the sensitivity of the OPNA–Tyr assay 
was also evaluated. Unexposed serum, plasma, and lysed whole blood samples were spiked 
with internal standard and calibrators to make a matrix-based calibration curve, then 
digested and extracted according to the validated method. As expected and recently 
demonstrated for the OPNA–BChE adduct method,36 there was no statistically significant 
difference in measured OPNA–Tyr values between serum and plasma. Lysed whole blood 
was analyzed to simulate samples where serum or plasma could not be harvested. The 
calibration curves were compared for consistency, response, and detection limit and were 
found to be indistinguishable between matrices. The uniformity of response in different 
matrices permits the preparation and quantitation of a variety of sample matrices in a single 
batch against a calibration curve constructed in any of the three matrices.
This high-throughput method allows for the accurate quantitation of clinical samples without 
sacrificing sensitivity. Using the reported method, 96 samples can be processed and ready 
for analysis in less than 4 h and analyzed by UHPLC-MS/MS in a single batch in less than 4 
h. Because sample preparation of a second set of 96 samples can be performed in parallel 
with instrumental analysis of the first, up to 480 samples can be prepared and analyzed in 24 
h by a single instrument. This level of throughput is defined by the simplicity of the sample 
preparation and the short UHPLC analysis time.
Matrix Effects and Extraction Recovery
OPNA–Tyr reference standard spiked matrix materials were used to evaluate SPE 
chemistries for matrix effects. Ionization efficiency and extraction recovery were both 
considered in the overall assessment of sensitivity and performance of the method. Polymer- 
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and silica-ligand sorbent beds composed of silica, cyanopropyl, mixed mode anion 
exchange, mixed mode cation exchange, phenyl, styrene divinylbenzene, pentafluorophenyl, 
and porous graphitic carbon were all assessed under conditions appropriate to the volume of 
sample and their mode(s) of extraction. The Strata SDB-L, a styrene divinylbenzene sorbent 
specifically designed for the purification of aromatic and hydrophobic compounds, provided 
the most consistent recovery and ionization data and proved to be a good all-around sorbent 
for OPNA–Tyr adducts (Table 3). The ionization efficiency generally increased with the 
composition of acetonitrile introduced during the gradient separation. This decrease in 
ionization efficiency for the early eluting compounds is consistent with reversed phase 
chromatography and desolvation of mobile phase with a high aqueous composition. 
VX/VM–Tyr adducts had the lowest recovery and were typically lost due to partial 
breakthrough during the wash steps of the extraction. Efforts to improve the recovery of 
VX/VM–Tyr resulted in higher recovery but also lower ionization efficiency and a net 
overall decrease in sensitivity for many of the other adducts.
UHPLC-MS/MS Optimization
The Atlantis-T3 column was selected after careful review of several separation phases and 
modes. A scouting gradient and linear solvent strength model were used to simplify 
chromatographic development.37 Gradient elution was chosen due to the large fraction of 
run time occupied between VX– and GD–Tyr. A separation producing a gradient retention 
factor (k*) of approximately 10 was required to produce baseline resolution of GA–Tyr from 
closely eluting low abundance mass interferences endogenous to serum. The final gradient 
time of 2 min and end point of 40% MPB was effective at producing a well-resolved 
chromatogram. The 30 s taken by the UHPLC autosampler to draw, wash, and load the next 
sample allowed approximately 4 column volumes of initial mobile phase conditions to re-
equilibrate the column prior to injection. The total time from injection to injection was 2.5 
min. Figure 2A shows an example of the resulting chromatographic separation on the 1.00 
ng/mL calibration standard. The retention time for each Tyr adduct was recorded during the 
two-month validation at each calibration and QC level, and the average retention time and 
precision are reported (Table 3). There was little variation in retention times, even when 
multiple column and mobile phase lots were used.
The high separation efficiency afforded by UHPLC demanded very short MS/MS dwell 
times per transition to obtain the 10–15 data points per peak we desired for quantitation. 
While the instrument was capable of acquiring acceptable data under these conditions, the 
signal-to-noise ratio was increased by utilizing the “Dynamic MRM” time function 
acquisition feature. The mass spectrometer was set to acquire transition-specific signal 
during a 30 s window centered on the compound’s expected retention time.
The MS/MS fragmentation for GA–, GB–, GD–, GF–, and VX–Tyr adducts have been 
previously reported.17,24 The product ion scans for VR– and 13CD3-VR–Tyr were collected 
at collision energies of 5, 15, and 25, and the resulting spectra were summed for the native 
and labeled compounds (Figure 3). The fragmentation for VR–Tyr is consistent with GB–, 
GD–, and GF–Tyr adducts with the collision induced disassociation (CID) of the nerve 
agent defining O-alkyl group resulting in m/z 260.1 and the additional loss of HCO2H to 
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yield m/z 214.1 as the two most abundant product ions. Fragmentation of VX/VM–Tyr also 
yielded m/z 260.1 and m/z 214.1; however, the loss of HCO2H to m/z 242.1 was more 
abundant than m/z 260.1 and thus used for confirmation. For GA–Tyr, the less abundant 
product ion of m/z 198.0 was chosen for confirmation instead of m/z 226.117 due to 
background contamination in the matrix.
In-source fragmentation resulting in the loss of the O-alkyl group was observed for GB–, 
GF–, GD–, VR–, and VX/VM–Tyr and increased with the stability of the O-alkyl leaving 
group. The most pronounced in-source fragmentation occurred for GF– and GD–Tyr. 
Decreasing the fragmentor voltage to 70 was sufficient to minimize the loss of cyclohexanol 
from GF–Tyr so the [M + H]+ ion of m/z 342.1 could be used for precursor selection of GF–
Tyr. However, the expected GD–Tyr [M + H]+ ion of m/z 344.1 was not observed, even at 
low fragmentor voltage, indicating instrument-related variation.17,24 Instead, the fragmentor 
voltage was increased to promote full in-source fragmentation loss of pinacolyl alcohol, and 
the resulting m/z 260.1 was used as the GD–Tyr precursor ion (Table 1). The CID of m/z 
260.1 resulted in loss of HCO2H to yield m/z 214.1 and further loss of HPO3 to yield m/z 
136.1. These MS/MS transitions had no background contamination and were used for 
quantitation and confirmation of GD–Tyr. Additionally, the MS/MS transitions from this in-
source fragmentation may prove to be useful as a general screen for O-alkyl 
methylphosphonate–Tyr adducts since GB–, GF–, VR– and VX/VM–Tyr were all detected 
in the same transitions and can be identified by retention time.
Linearity, Accuracy, Precision, and Limits of Detection
Validation data was collected from 20 processed calibration curves that were recorded over 
a period of two months (Table 4). Calibration curves were linear for all Tyr adducts with a 
coefficient of determination value (R2) ≥0.995 over a range of 0.100–50.0 ng/mL for GB– 
and VR–Tyr and a range of 0.250–50.0 ng/mL for GA–, GD–, GF–, VX–, and VM–Tyr. 
The mean accuracies for all Tyr adducts were 99.3–115% at 0.250 ng/mL, 94.9–100% at 
2.50 ng/mL, and 98.5–101% at 25.0 ng/mL. The inter-assay precision on the same samples 
was 6.16–17.3, 4.52–8.11, and 3.30–7.70%, respectively. The three different QC samples 
were prepared and analyzed with each calibration curve, and the mean concentration and 
precision values were characterized. The inter-assay precision was 6.96–13.6% for QCL, 
3.78–8.92% for QCH, and 7.48–17.2% for QCD. The intra-assay precision was evaluated 
using five simultaneous preparations of QCL, QCH, and QCD samples and was found to be 
between 1.54 and 9.72% for all adducts and all concentrations (Table 5). As expected, GA–
Tyr was the most variable adduct measured for the calibrators and QC samples, regardless of 
concentration, although the precision was still within acceptable limits (CV ≤ 20%). The 
LOD values were calculated using the Taylor method of evaluating the standard deviation at 
known concentrations. The LOD values reported were calculated using the quantitation ion 
(Table 4) and are comparable to those reported for GB–, GD–, and VX–Tyr in rat plasma;24 
however, this is the first report of limits of detection for GA–, GF–, and VR–Tyr. The LRL 
was chosen so that it was above the LOD with the confirmation ion reliably detected, and a 
CIR could be established for each adduct. The CIRs were calculated to be 1.10 (±0.137), 
1.31 (±0.128), 6.94 (±0.502), 0.867 (±0.085), 1.55 (±0.151), and 0.692 (±0.078) for GA–, 
GB–, GD–, GF–, VR–, and VX/VM–Tyr adducts, respectively.
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The synthetic OPNA–Tyr standards were stored in water at −20 °C for 9 months with no 
signs of degradation. Similarly, pooled plasma and serum samples independently spiked 
with GA, GB, GD, GF, VR, VX, and VM were stored at −80 °C with no signs of 
degradation in 9 months of testing. Initially, prepared samples were reconstituted in MPA 
following the removal of the extraction solvents; however, the signal intensity for GA–Tyr 
in MPA reconstituted samples decreased dramatically and was undetectable after 3 days 
stored on the instrument at 4 °C. Removal of the 0.1% formic acid from the reconstitution 
solvent eliminated the poor short-term stability of the extracted GA–Tyr samples.
It has been reported that adducts to HSA are stable and do not lose the agent defining O-
alkyl side chain22,38 in a process similar to aging on cholinesterase.39,40 Still, there has been 
little discussion of the fate of HSA nerve agent adducts when exposed to conditions that 
would otherwise produce an aged cholinesterase adduct. As a model, GB was added to 
serum (396 ng/mL) which was then divided into two pools. One pool was stored at −80 °C, 
and the second was held at 40 °C for 96 h. As previously shown, these conditions are 
suitable for producing an aged methylphosphonate (MeP) adduct on BChE.41 The samples 
were characterized (n ≥ 8) yielding the result of 11.8 (±1.14) ng/mL GB–Tyr for the material 
stored at −80 °C and 2.37 (±0.194) ng/mL for the material stored at 40 °C. Evidence of O-
alkyl side chain loss from the GB–Tyr adduct was not observed when compared to a 
standard of MeP–Tyr; however, the 80% reduction in GB–Tyr at a storage temperature of 40 
°C is an important finding. The distinction between O-alkyl hydrolysis and overall adduct 
loss must be considered when attempting to measure Tyr adducts in samples that have not 
been collected, transported, or stored properly. Furthermore, it is likely that adduct loss will 
also occur in vivo, prior to specimen collection. A more detailed study of the degradation 
kinetics for additional OP–Tyr adducts is currently underway.
Nerve Agent Spiked Materials and Convenience Samples
Various OPNA spiked materials were characterized for Tyr adducts (n = 10) using the 
validated method (Table 6). Figure 2B–H contains representative chromatograms for plasma 
samples before and after the addition of nerve agents. The plasma samples were spiked with 
nerve agent so that complete BChE inhibition was not reached. These materials were used to 
assess the detection and reporting limit for nerve agents adducted to Tyr in terms of BChE 
percent inhibition. For the G-series agents, the extrapolated lower reporting limit is 
equivalent to approximately 2–5% BChE inhibition; although, based on the detection limits, 
it may be possible to identify nerve agent adducts to Tyr below 2% BChE inhibition. 
Approximately 10–20% of the spiked nerve agent was detected as a Tyr adduct for the G-
series agents. Assuming that the measured Tyr adducts are predominately from HSA and 
that the normal range of HSA is 35–55 mg/mL in plasma,42 these values represent an 
approximately 0.001–0.004% molar adduction to HSA for GA, GB, GD, and GF.
As shown in Table 6, there is a clear difference in reactivity with Tyr between the G-series 
and the V-series agents with less than 1% of the spike of VX and VR binding to Tyr. The 
low reactivity of VX to HSA (Figure 2B) has previously been reported17 and suggested to 
be related to the nature of the leaving group. The reactivity of VR to Tyr is similar to that of 
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VX (Figure 2F); however, while VM appears to be more reactive with Tyr than the other V-
series investigated (Figure 2C), the direct comparison of the reactivity of VM to VX and VR 
with tyrosine should be qualified by confounding factors such as the different spiking 
conditions and concentrations used during in vitro preparations of these materials. As a 
whole, the V-series adducts are still much lower than observed for the G-series adducts.
To assess background and possible interferences, commercially obtained serum samples 
with no expectation of nerve agent exposure were prepared and analyzed. No peaks 
corresponding to any of the OPNA–Tyr adducts measured by the reported method were 
detected in the 96 convenience set samples studied. The selected SRM transitions and their 
ratio to one another coupled with the high-efficiency chromatographic separation provide 
excellent selectivity for the OPNA–Tyr adducts.
CONCLUSION
A new method for the detection of GA, GB, GD, GF, VR, VX, and VM exposure through 
the measurement of Tyr adducts in blood products has been developed and validated which 
may extend the time postevent that the exact OPNA of exposure may be identified in clinical 
specimens. The simplified sample preparation provides high accuracy and precision, low 
background interference, and low limits of detection using only 50 µL of whole lysed blood, 
plasma, or serum without the need for HSA enrichment. Rapid UHPLC-MS/MS analysis 
coupled with high throughput sample preparation allows up to 480 samples to be processed 
and analyzed per day per single instrument. Synthetic calibrators and OPNA spiked QC 
materials have been shown to be stable for at least 9 months when stored at −20 °C and −80 
°C, respectively. The method has been used to characterize clinical samples exposed to live 
nerve agent in vitro and to assess the effect of sample aging conditions for the GB–Tyr 
adduct. Additionally, promoting in-source fragmentation may allow the described method to 
be readily adapted for use as a general screen for exposure to prohibited CWC Schedule 1 
nerve agents containing an O-alkyl methylphosphonate group.
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Structures of organophosphorus nerve agent–tyrosine adducts. GA–Tyr, R1 = ethyl and R2 = 
dimethylamino; GB–Tyr, R1 = isopropyl and R2 = methyl; GD–Tyr, R1 = pinacolyl and R2 = 
methyl; GF–Tyr, R1 = cyclohexyl and R2 = methyl; VR–Tyr, R1 = isobutyl and R2 = methyl; 
VX/VM–Tyr, R1 = ethyl and R2 = methyl. VX and VM adducts to tyrosine cannot be 
differentiated.
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Overlay of extracted ion chromatograms of the OPNA–Tyr adducts. (A) Blank plasma 
spiked with 1.00 ng/mL synthetic standards. (B–H, black trace) Blank plasma and (colored 
trace) detected tyrosine adduct following separate and independent addition of 
corresponding nerve agent to the blanks.
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Product ion scans for VR– and 13CD3-VR–Tyrosine.
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Table 2
Comparison between the Digestion of Total Protein and Albumin Enriched Plasma Exposed to G-Series Nerve 
Agents









GA 3.24 (10.9) 1.02 (47.1) 104
GB 4.54 (5.10) 4.23 (13.0) 7.04
GD 7.48 (8.56) 6.44 (13.1) 15.0
GF 3.82 (7.50) 3.75 (13.7) 1.66
a
The difference (%) was calculated as 100 × the absolute value of [(total protein digest concentration − albumin-enriched digest concentration)/
(average of total protein and albumin-enriched digests)].
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Table 3








VX–Tyr, VM–Tyr 0.993 (1.01%) 56.0 37.8
GB–Tyr 1.18 (0.840%) 66.7 64.9
GA–Tyr 1.26 (0.814%) 53.4 89.9
VR–Tyr 1.43 (0.741%) 64.0 74.8
GF–Tyr 1.64 (0.720%) 88.5 67.8
GD–Tyr 1.77 (0.670%) 92.1 69.9
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Table 6

















GA 67.1 123 10.2 (±1.10) 8.29
GB 88.1 143 15.0 (±0.76) 10.5
GD 87.8 110 21.7 (±1.86) 19.7
GF 76.9 111 11.2 (±0.848) 10.1
VR 53.3 74.9 0.443 (±0.063) 0.591
VX 92.1 74.9 0.625 (±0.278) 0.834
VM 99.0 313 10.4 (±1.73) 3.32
a
[1 − (prespike BChE activity/postspike BChE activity)] × 100.
Anal Chem. Author manuscript; available in PMC 2015 October 21.
